KLK3 and prostate carcinoma: Pre-treatment PSA data were available for a subset of prostate cancer patients (n = 23) and patients with benign conditions (n = 5), with blood samples obtained within 100 days of those used for exosomal TF-Ag-α analysis to ensure comparability.